Contact Us
Drug Search Results
More Filters [+]

Peramivir

Alternative Names: peramivir, rapivab
Latest Update: 2024-07-01
Latest Update Note: News Article

Product Description

Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22339187/)

Mechanisms of Action: NEU Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Belgium | Canada | European Medicines Agency | Germany | Hungary | Ireland | Italy | Japan | Korea | Lithuania | Poland | Portugal | Sweden | Taiwan | United States

Approved Indications: Influenza, Human

Known Adverse Events: Diarrhea

Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Peramivir

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20131184

P3

Recruiting

Influenza, Human

None

CTR20131182

P3

Recruiting

Influenza, Human

None

Recent News Events

Date

Type

Title

07/01/2024

News Article

 NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections

06/24/2024

News Article

 A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

06/20/2024

News Article

 A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

06/04/2024

News Article

 The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions